DCTD Programs
FOLLOW DCTDLast Updated: 05/26/2017
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Schedule of DCTD Presentations
Several DCTD staff members will present information at the ASCO Annual Meeting 
in Chicago, IL from June 2-6, 2017 via the following three presentation categories:
Oral Presentations
| Time | Title | Presenter | Location |
|---|---|---|---|
| Friday, June 2 | |||
| 1:00 PM - 1:20 PM | The State of the Art in High-Grade Serous Ovarian Cancer: Update on high-grade serous ovarian carcinoma
|
Elise Kohn, MD, Cancer Therapy Evaluation Program | S406 |
| 1:40 PM - 2:00 PM | The State of the Art in High-Grade Serous Ovarian Cancer: Creating synthetic lethality
|
Percy Ivy, MD, Cancer Therapy Evaluation Program |
S406 |
Poster Presentations
| Time | Title | Presenter | Location |
|---|---|---|---|
| Saturday, June 3 | |||
| 1:15 PM – 4:45 PM | Survival profile in breast cancer molecular subtypes without systemic and locoregional Treatment.
|
Sherry X. Yang, MD, PhD, Developmental Therapeutics Program |
Hall A; Abstract 11599; Poster Board 299 |
| 1:15 PM – 4:45 PM | Antitumor activity of indenoisoquinoline inhibitors of topoisomerase 1 (TOP1) via apoptosis and autophagocytosis pathways in animal models.
|
Robert Kinders, PhD, Pharmacodynamic Assay Development and Implementation Section (PADIS) |
Hall A; Abstract 11588; Poster Board 288 |
| Monday, June 5 | |||
| 8:00 AM - 11:30 AM | A phase I trial of TRC102 (methoxyamine HCL) with temozolamide (TMZ) in patients with solid tumors and lymphomas.
|
Robert S. Meehan, MD, Early Clinical Trials Development Program |
Hall A; Abstract 2518; Poster Board 10 |
| 8:00 AM - 11:30 AM | Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.
|
Geraldine O’Sullivan Coyne, MD, PhD, Early Clinical Trials Development Program | Hall A; Abstract 2558; Poster Board 50 |
| 8:00 AM - 11:30 AM | Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors.
|
Geraldine O’Sullivan Coyne, MD, PhD, Early Clinical Trials Development Program | Hall A; Abstract TPS2609; Poster Board 94B |
| 8:00 AM – 11:30 AM | Suitability factors of core needle biopsies for pharmacodynamic (PD) studies.
|
Ralph E. Parchment, PhD, Office of the Director; Frederick National Laboratory for Cancer Research | Hall A; Abstract 2540; Poster Board 32 |
| 1:15 PM - 4:45 PM | National coverage analyses for NCI clinical trials: A pilot project to reduce participation barriers.
|
Andrea Denicoff, RN, MS, Cancer Therapy Evaluation Program | Hall A; Abstract 6542; Poster Board 364 |
| 1:15 PM - 4:45 PM | Transparency around disapproval reasons of early-phase trial proposals submitted to the National Cancer Institute (NCI).
|
Holly A. Massett, PhD, Cancer Therapy Evaluation Program | Hall A; Abstract 6585; Poster Board 407 |
Meet-the-Expert Presentations
NCI Exhibit Booth # 4052
| Time | Topic | Presenter |
|---|---|---|
| Saturday, June 3 | ||
| 9:30 AM – 10:00 AM | NCI-MATCH Trial (Molecular Analysis for Therapy Choice) | Alice Chen, MD, Early Clinical Trials Development Program |
| 10:15 AM – 10:45 AM | CTCAE- Common Terminology Criteria for Adverse Events | Alice Chen, MD, Early Clinical Trials Development Program |
| 12:30 PM – 1:00 PM | Everything You Wanted to Know about the NCI-Pediatric MATCH Trial | Nita Seibel, MD, Cancer Therapy Evaluation Program |
| Monday, June 5 | ||
| 12:30 PM – 1:00 PM | The NCI Formulary: A Cancer Moonshot Initiative | Jason Cristofaro, JD, PhD, Office of the Director |
| 1:15 PM – 1:45 PM | Precision Medicine in Lung Cancer Trials | Shakun Malik, MD, Cancer Therapy Evaluation Program |
| 2:00 PM – 2:30 PM | Biomarker Development in NCI Early Phase Trials | Tracy Lively, PhD, Cancer Diagnosis Program |
| 3:30 PM – 4:00 PM | Partnering with the NCI Developmental Therapeutics Program for Developing New Cancer Treatments | Rose Aurigemma, PhD, Developmental Therapeutics Program |